{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-020819","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.766258+00:00","generated_at":"2026-06-15T04:12:32.090024+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aeglea BioTherapeutics reports Q1 2023 net loss of $18.4M; cash at $39.8M","bullets":["Cash, equivalents, marketable securities, restricted cash totaled $39.8M as of March 31, 2023.","Revenue of $0.2M from Immedica Pharma license/supply agreement for pegzilarginase in Europe/Middle East.","R&D expenses fell to $13.8M from $17.0M; G&A expenses fell to $5.2M from $8.8M year-over-year.","Net loss improved to $18.4M from $24.4M in Q1 2022; includes $1.7M non-cash stock compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-020819","json":"https://secwatch.observer/filing/0000950170-23-020819.json","markdown":"https://secwatch.observer/filing/0000950170-23-020819.md","text":"https://secwatch.observer/filing/0000950170-23-020819.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000095017023020819/0000950170-23-020819-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000095017023020819/agle-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:12:32.090024+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c459efb25e42fd7006fd4686f07377714b74b75d","claim":"Spyre Therapeutics, Inc. reported first quarter 2023 results: revenue $0.2 million, net income Net loss totaled $18.4 million.","evidence_excerpt":"31, 2023, Aeglea had available cash and cash equivalents, marketable securities and restricted cash of $39.8 million. Aeglea recognized development fee and royalty revenues of $0.2 million in the first quarter of 2023, as a result of its license and supply agreement with Immedica Pharma AB for the commercial rights to pegzilarginase in Europe and several countries","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000095017023020819/0000950170-23-020819-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2023"},{"label":"Revenue","value":"$0.2 million"},{"label":"Net income","value":"Net loss totaled $18.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}